Dulaglutide (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Dulaglutide" in English language version.

refsWebsite

Global rank English rank

14nih.gov

4^th place

9doi.org

2^nd place

4web.archive.org

1^st place

3semanticscholar.org

11^th place

8^th place

3fda.gov

447^th place

338^th place

2drugs.com

399^th place

333^rd place

2lilly.com

low place

2clincalc.com

3,912^th place

2,496^th place

1tga.gov.au

3,984^th place

2,622^nd place

1canada.ca

1,712^th place

1,063^rd place

1europa.eu

68^th place

117^th place

canada.ca

"Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

clincalc.com

"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Dulaglutide Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.

doi.org

Tibble CA, Cavaiola TS, Henry RR (May 2013). "Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature". Expert Review of Endocrinology & Metabolism. 8 (3): 247–259. doi:10.1586/eem.13.20. PMID 30780817. S2CID 73313508.
Terauchi Y, Satoi Y, Takeuchi M, Imaoka T (July 2014). "Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study". Endocrine Journal. 61 (10): 949–959. doi:10.1507/endocrj.ej14-0147. PMID 25029955.
Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, et al. (June 2017). "Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis". BMJ. 357: j2499. doi:10.1136/bmj.j2499. PMC 5463186. PMID 28596247.{{cite journal}}: CS1 maint: overridden setting (link)
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z (August 2014). "Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)". Diabetes Care. 37 (8): 2149–2158. doi:10.2337/dc13-2761. PMC 4113177. PMID 24742660.
Amblee A (April 2014). "Dulaglutide for the treatment of type 2 diabetes". Drugs of Today. 50 (4): 277–289. doi:10.1358/dot.2014.50.4.2132740. PMID 24918645.
Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E (February 2014). "Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials". Diabetes Research and Clinical Practice. 103 (2): 269–275. doi:10.1016/j.diabres.2014.01.010. PMID 24485345. S2CID 33922845.
Samson SL, Garber A (April 2013). "GLP-1R agonist therapy for diabetes: benefits and potential risks". Current Opinion in Endocrinology, Diabetes, and Obesity. 20 (2): 87–97. doi:10.1097/MED.0b013e32835edb32. PMID 23403741. S2CID 6933973.
Nadkarni P, Chepurny OG, Holz GG (2014). "Regulation of glucose homeostasis by GLP-1". Progress in Molecular Biology and Translational Science. 121: 23–65. doi:10.1016/B978-0-12-800101-1.00002-8. ISBN 978-0-12-800101-1. PMC 4159612. PMID 24373234.
Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, et al. (March 2021). "Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)". Diabetes Care. 44 (3): 765–773. doi:10.2337/dc20-1473. PMC 7896253. PMID 33397768.{{cite journal}}: CS1 maint: overridden setting (link)

drugs.com

"Dulaglutide international". Drugs.com. 3 January 2020. Retrieved 4 February 2020.
"Dulaglutide (Trulicity) Use During Pregnancy". Drugs.com. 15 July 2019. Retrieved 4 February 2020.

europa.eu

ema.europa.eu

"Trulicity EPAR". European Medicines Agency (EMA). 17 September 2018. Retrieved 23 February 2020.

fda.gov

"FDA approves Trulicity to treat type 2 diabetes" (Press release). U.S. Food and Drug Administration (FDA). 18 September 2014. Archived from the original on 20 April 2016. Retrieved 4 February 2020. This article incorporates text from this source, which is in the public domain.
"Risk Evaluation and Mitigation Strategy (REMS)". United States Food and Drug Administration. September 2014. Archived from the original on 5 March 2021. Retrieved 24 March 2020.

accessdata.fda.gov

"Drug Approval Package: Trulicity (dulaglutide) NDA #125469". U.S. Food and Drug Administration (FDA). 27 October 2014. Archived from the original on 2 July 2015. Retrieved 4 February 2020.

lilly.com

investor.lilly.com

"Lilly's Once-Weekly Dulaglutide Shows Non-Inferiority to Liraglutide in Head-to-Head Phase III Trial for Type 2 Diabetes" (Press release). Eli Lilly. 25 February 2014.
"Trulicity (dulaglutide) is the first and only type 2 diabetes medicine approved to reduce cardiovascular events in adults with and without established cardiovascular disease". Eli Lilly and Company (Press release). 21 February 2020. Retrieved 23 February 2020.

nih.gov

pubmed.ncbi.nlm.nih.gov

Tibble CA, Cavaiola TS, Henry RR (May 2013). "Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature". Expert Review of Endocrinology & Metabolism. 8 (3): 247–259. doi:10.1586/eem.13.20. PMID 30780817. S2CID 73313508.
Terauchi Y, Satoi Y, Takeuchi M, Imaoka T (July 2014). "Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study". Endocrine Journal. 61 (10): 949–959. doi:10.1507/endocrj.ej14-0147. PMID 25029955.
Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, et al. (June 2017). "Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis". BMJ. 357: j2499. doi:10.1136/bmj.j2499. PMC 5463186. PMID 28596247.{{cite journal}}: CS1 maint: overridden setting (link)
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z (August 2014). "Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)". Diabetes Care. 37 (8): 2149–2158. doi:10.2337/dc13-2761. PMC 4113177. PMID 24742660.
Amblee A (April 2014). "Dulaglutide for the treatment of type 2 diabetes". Drugs of Today. 50 (4): 277–289. doi:10.1358/dot.2014.50.4.2132740. PMID 24918645.
Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E (February 2014). "Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials". Diabetes Research and Clinical Practice. 103 (2): 269–275. doi:10.1016/j.diabres.2014.01.010. PMID 24485345. S2CID 33922845.
Samson SL, Garber A (April 2013). "GLP-1R agonist therapy for diabetes: benefits and potential risks". Current Opinion in Endocrinology, Diabetes, and Obesity. 20 (2): 87–97. doi:10.1097/MED.0b013e32835edb32. PMID 23403741. S2CID 6933973.
Nadkarni P, Chepurny OG, Holz GG (2014). "Regulation of glucose homeostasis by GLP-1". Progress in Molecular Biology and Translational Science. 121: 23–65. doi:10.1016/B978-0-12-800101-1.00002-8. ISBN 978-0-12-800101-1. PMC 4159612. PMID 24373234.
Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, et al. (March 2021). "Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)". Diabetes Care. 44 (3): 765–773. doi:10.2337/dc20-1473. PMC 7896253. PMID 33397768.{{cite journal}}: CS1 maint: overridden setting (link)

ncbi.nlm.nih.gov

Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, et al. (June 2017). "Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis". BMJ. 357: j2499. doi:10.1136/bmj.j2499. PMC 5463186. PMID 28596247.{{cite journal}}: CS1 maint: overridden setting (link)
Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z (August 2014). "Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)". Diabetes Care. 37 (8): 2149–2158. doi:10.2337/dc13-2761. PMC 4113177. PMID 24742660.
Nadkarni P, Chepurny OG, Holz GG (2014). "Regulation of glucose homeostasis by GLP-1". Progress in Molecular Biology and Translational Science. 121: 23–65. doi:10.1016/B978-0-12-800101-1.00002-8. ISBN 978-0-12-800101-1. PMC 4159612. PMID 24373234.
Frias JP, Bonora E, Nevarez Ruiz L, Li YG, Yu Z, Milicevic Z, et al. (March 2021). "Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11)". Diabetes Care. 44 (3): 765–773. doi:10.2337/dc20-1473. PMC 7896253. PMID 33397768.{{cite journal}}: CS1 maint: overridden setting (link)

dailymed.nlm.nih.gov

"Trulicity- dulaglutide injection, solution". DailyMed. 3 January 2024. Retrieved 26 August 2024.

semanticscholar.org

api.semanticscholar.org

Tibble CA, Cavaiola TS, Henry RR (May 2013). "Longer acting GLP-1 receptor agonists and the potential for improved cardiovascular outcomes: a review of current literature". Expert Review of Endocrinology & Metabolism. 8 (3): 247–259. doi:10.1586/eem.13.20. PMID 30780817. S2CID 73313508.
Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E (February 2014). "Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials". Diabetes Research and Clinical Practice. 103 (2): 269–275. doi:10.1016/j.diabres.2014.01.010. PMID 24485345. S2CID 33922845.
Samson SL, Garber A (April 2013). "GLP-1R agonist therapy for diabetes: benefits and potential risks". Current Opinion in Endocrinology, Diabetes, and Obesity. 20 (2): 87–97. doi:10.1097/MED.0b013e32835edb32. PMID 23403741. S2CID 6933973.

tga.gov.au

"Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.

web.archive.org

"FDA approves Trulicity to treat type 2 diabetes" (Press release). U.S. Food and Drug Administration (FDA). 18 September 2014. Archived from the original on 20 April 2016. Retrieved 4 February 2020. This article incorporates text from this source, which is in the public domain.
"Drug Approval Package: Trulicity (dulaglutide) NDA #125469". U.S. Food and Drug Administration (FDA). 27 October 2014. Archived from the original on 2 July 2015. Retrieved 4 February 2020.
"The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
"Risk Evaluation and Mitigation Strategy (REMS)". United States Food and Drug Administration. September 2014. Archived from the original on 5 March 2021. Retrieved 24 March 2020.